Reviewing Advanced Medical Isotope (OTCMKTS:RDGL) & Crescent Capital BDC (NASDAQ:CCAP)

Advanced Medical Isotope (OTCMKTS:RDGL) and Crescent Capital BDC (NASDAQ:CCAP) are both small-cap finance companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, analyst recommendations, institutional ownership, dividends, profitability, earnings and risk.

Institutional and Insider Ownership

49.5% of Crescent Capital BDC shares are held by institutional investors. 18.5% of Advanced Medical Isotope shares are held by company insiders. Comparatively, 1.1% of Crescent Capital BDC shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Advanced Medical Isotope and Crescent Capital BDC, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Advanced Medical Isotope	0	0	0	0	0.00
Crescent Capital BDC	0	3	3	1	2.71

Crescent Capital BDC has a consensus target price of $15.60, suggesting a potential upside of 26.11%. Given Crescent Capital BDC’s stronger consensus rating and higher possible upside, analysts clearly believe Crescent Capital BDC is more favorable than Advanced Medical Isotope.

Valuation and Earnings

This table compares Advanced Medical Isotope and Crescent Capital BDC”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Advanced Medical Isotope	$70,000.00	581.30	-$2.91 million	($0.01)	-8.43
Crescent Capital BDC	$167.29 million	2.73	$34.51 million	$0.94	13.16

Crescent Capital BDC has higher revenue and earnings than Advanced Medical Isotope. Advanced Medical Isotope is trading at a lower price-to-earnings ratio than Crescent Capital BDC, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Advanced Medical Isotope has a beta of -0.64, indicating that its share price is 164% less volatile than the S&P 500. Comparatively, Crescent Capital BDC has a beta of 0.55, indicating that its share price is 45% less volatile than the S&P 500.

Profitability

This table compares Advanced Medical Isotope and Crescent Capital BDC’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Advanced Medical Isotope	-6,144.90%	N/A	-113.56%
Crescent Capital BDC	20.64%	9.32%	4.07%

Summary

Crescent Capital BDC beats Advanced Medical Isotope on 13 of the 15 factors compared between the two stocks.

About Advanced Medical Isotope

Vivos Inc., a radiation oncology medical device company, develops brachytherapy devices for the treatment of non-resectable tumors in the United States. It develops yttrium-90 based RadioGel device, an injectable particle-gel for brachytherapy radiation treatment of cancerous tumors in people and animals; and IsoPet for the treatment of solid tumors in animals. The company was formerly known as Advanced Medical Isotope Corporation and changed its name to Vivos Inc. in December 2017. Vivos Inc. was incorporated in 1994 and is headquartered in Richland, Washington.

About Crescent Capital BDC

Crescent Capital BDC, Inc. is as a business development company private equity / buyouts and loan fund. It specializes in directly investing. It specializes in middle market. The fund seeks to invest in United States.